Joint activation of TLR4 causes a dose- and time-dependent hyperalgesia.
Joint hyperalgesia caused by TLR4 activation depends on MYD88 signaling.
This pathway leads to joint hyperalgesia through mechanisms dependent on cytokines and chemokines production.
TLR4/MyD88 signaling pathway inhibitors might be useful for the treatment of inflammatory joint pain.